Summary: In this poster, Catalent Biologics outlines a strategy using inductively coupled plasma-mass spectrometry (ICP-MS) to conduct trace-level multiple analysis...

Summary: ADCs are an important class of biologic drugs that are well-represented in clinical trials for oncology and other indications. These medicines harbor both...

Summary: Pharma companies are looking for ways to speed up their biologics to market in order to meet the patients' needs. During this webinar...

Summary: Watch this webinar to see an overview and case study of process characterization performed by Catalent...

Summary: Pharma companies are constantly looking for ways to save money within their operations. One way of doing this is to improve upon efficiencies within its manufacturing...

Summary: Current state-of-the-art continuous manufacturing technologies are being developed and implemented to manufacture a wide variety of products including monoclonal antibodies, recombinant proteins, and other biological modalities...

Summary: Current state-of-the-art continuous manufacturing technologies are being developed and implemented to manufacture a wide variety of products including...

Summary: Discover how a pilot formulation study at the early drug substance development stage can make things considerably easier at the manufacturing stage.

Summary: As the biologics industry continues to grow, biopharmaceutical companies are evaluating continuous processing as a potential means to improve efficiencies. There are many factors to consider when determining whether continuous processing should be adopted, and if so, what adoption strategy should be used...

Summary: Antibody drug conjugates (ADCs) have become de rigueur for pharmaceutical oncology drug development pipelines. There are more than 40 ADCs undergoing clinical trials and many more in preclinical development...